Comparison of Effectiveness of Atorvastatin 10 mg Versus 80 mg in Reducing Major Cardiovascular Events and Repeat Revascularization in Patients With Previous Percutaneous Coronary Intervention (Post Hoc Analysis of the Treating to New Targets [TNT] Study)

American Journal of Cardiology

Volumn 102, Issue 10, 2008, Pages 1312-1317

  Johnson, Colleen ^a   Waters, David D ^a   DeMicco, David A ^b   Breazna, Andrei ^b   Bittner, Vera ^d   Greten, Heiner ^e   Grundy, Scott M ^f   LaRosa, John C ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PFIZER INC   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e DEPARTMENT OF CARDIOLOGY   (Germany)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEART MUSCLE REVASCULARIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRROLES; REOPERATION;

EID: 55249111846     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.07.023     Document Type: Article

References (17)

1. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., Gotto A.M., Greten H., Kastelein J.J., Shepherd J., Wenger N.K., and Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
2. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., Larsen M.L., Bendiksen F.S., Lindahl C., Szarek M., Tsai J., and Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 (2005) 2437-2445
3. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., Joyal S.V., Hill K.A., Pfeffer M.A., Skene A., and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
4. Waters D.D., Guyton J.R., Herrington D.M., McGowan M.P., Wenger N.K., Shear C., and Treating to New Targets (TNT) Investigators. Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 93 (2004) 154-158
5. Shah S.J., Waters D.D., Barter P., Kastelein J.J.P., Shepherd J., Wenger N.K., DeMicco D.A., Breazna A., and LaRosa J.C. Intensive lipid-lowering with atorvastatin for secondary prevention in patients following coronary artery bypass surgery. J Am Coll Cardiol 51 (2008) 1938-1943
6. Weintraub W.S., Boccuzzi S.J., Klein J.L., Kosinski A.S., King III S.B., Ivanhoe R., Cedarholm J.C., Stillabower M.E., Talley J.D., DeMaio S.J., et al., Lovastatin Restenosis Trial Study Group. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 331 (1994) 1331-1337
7. Bertrand M.E., McFadden E.P., Fruchart J.C., Van Belle E., Commeau P., Grollier G., Bassand J.P., Machecourt J., Cassagnes J., Mossard J.M., et al., PREDICT Trial Investigators. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. J Am Coll Cardiol 30 (1997) 863-869
8. Serruys P.W., Foley D.P., Jackson G., Bonnier H., Macaya C., Vrolix M., Branzi A., Shepherd J., Suryapranata H., de Feyter P.J., et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur Heart J 20 (1999) 58-69
9. Serruys P.W., de Feyter P., Macaya C., Kokott N., Puel J., Vrolix M., Branzi A., Bertolami M.C., Jackson G., Strauss B., and Meier B. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 287 (2002) 3215-3222
10. Mood G.R., Bavry A.A., Roukoz H., and Bhatt D.L. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 100 (2007) 919-923
11. LaRosa J.C., Grundy S.M., Kastelein J.J., Kostis J.B., Greten H., and Treating to New Targets (TNT) Steering Committee and Investigators. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets [TNT] study). Am J Cardiol 100 (2007) 747-752
12. Glaser R., Selzer F., Faxon D.P., Laskey W.K., Cohen H.A., Slater J., Detre K.M., and Wilensky R.L. Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation 111 (2005) 143-149
13. Lehmann K.G., Maas A.C., van Domburg R., de Feyter P.J., van den Brand M., and Serruys P.W. Repeat interventions as a long-term treatment strategy in the management of progressive coronary artery disease. J Am Coll Cardiol 27 (1996) 1398-1405
14. Nissen S.E., Tuzcu E.M., Schoenhagen P., Brown B.G., Ganz P., Vogel R.A., Crowe T., Howard G., Cooper C.J., Brodie B., et al., REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
15. Takano M., Mizuno K., Yokoyama S., Seimiya K., Ishibashi F., Okamatsu K., and Uemura R. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol 42 (2003) 680-686
16. Yokoyama M., Komiyama N., Courtney B.K., Nakayama T., Namikawa S., Kuriyama N., Koizumi T., Nameki M., Fitzgerald P.J., and Komuro I. Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study. Am Heart J 150 (2005) 287e1-287e7
17. Schwartz G.G., Olsson A.G., Ezekowitz M.D., Ganz P., Oliver M.F., Waters D., Zeiher A., Chaitman B.R., Leslie S., and Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 265 (2001) 1711-1718